GO:0097278 complement-dependent cytotoxicity: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097278 complement-dependent cytotoxicity (CDC) is defined as cell killing caused by the membrane attack complex formed following complement activation.
• CDC is measured experimentally by incubating target cells with complement-active serum and a specific antibody, then quantifying lysis or viability.
• The membrane attack complex (MAC) is the terminal effector of the complement cascade and directly permeabilizes target cell membranes.
• CDC is central to antibody-mediated rejection in transplantation and to autoimmune cytopenias such as immune thrombocytopenia.
• Tumor cells can evade CDC by up-regulating complement inhibitors such as CD59, a mechanism linked to NANOG expression.
• Gene-edited cells and CRISPR models are increasingly used to dissect CDC resistance and to evaluate xenotransplantation compatibility.
Description
Complement-dependent cytotoxicity (CDC), annotated as GO:0097278, is a biological process in which target cells are killed by the membrane attack complex (MAC) that assembles after activation of the complement system. In laboratory practice, CDC is most often studied by exposing target cells to a specific antibody in the presence of complement-active serum, after which cell lysis or viability is quantified. The assay format has become a standard tool in histocompatibility testing, autoantibody characterization, and therapeutic antibody evaluation. Because the readout is a direct functional consequence of complement activation, CDC assays provide a sensitive way to detect antibodies that fix complement and to compare the susceptibility of different cell types to MAC-mediated killing. The process matters because it links humoral immunity to irreversible cell damage. In transplantation, donor-specific antibodies that trigger CDC are a major cause of graft injury, and CDC crossmatch assays are used to identify unacceptable antigen mismatches before transplantation. In autoimmunity, complement-fixing autoantibodies can drive destruction of platelets, red cells, and other targets, as seen in immune thrombocytopenia. In oncology, the same pathway can be harnessed by therapeutic antibodies, while tumor cells may acquire resistance through up-regulation of complement inhibitors such as CD59. Recent work has extended CDC research to gene-edited cells and xenotransplantation, where the goal is to predict whether human complement will lyse pig cells carrying specific genetic modifications. These studies highlight that CDC is not a fixed property of a cell but depends on the balance between complement activation and membrane-bound regulators. Understanding this balance at the molecular level is therefore essential for interpreting CDC assays and for designing cells with desired sensitivity or resistance.
complement-dependent cytotoxicity At A Glance
| GO ID | GO:0097278 |
|---|---|
| GO term | complement-dependent cytotoxicity |
| Ontology | biological_process |
| Synonym | none listed in QuickGO |
| Definition | Cell killing caused by the membrane attack complex formed following complement activation |
| Major function | Antibody- and complement-mediated lysis of target cells |
| Key effector | Membrane attack complex (MAC) assembled from complement components |
| Common assay | Incubation of target cells with antibody and complement-active serum followed by viability or lysis readout |
| Disease relevance | Transplant rejection, autoimmune cytopenias, tumor immune evasion |
What Is GO:0097278?
According to the Gene Ontology, GO:0097278 complement-dependent cytotoxicity is the cell killing that results from the membrane attack complex formed following complement activation. In other words, it is a complement-driven death process in which the terminal complement pathway assembles a pore-forming complex on a target cell membrane, leading to loss of membrane integrity and cell lysis. The term is defined by the causal mechanism (MAC formation after complement activation) rather than by a specific cell type or antibody, so it applies to any target cell that becomes opsonized and attacked by complement.
Why Is complement-dependent cytotoxicity Important in Cell Biology?
CDC is important because it is a direct, measurable link between antibody recognition and target cell destruction, making it a central readout in transplantation, autoimmunity, and therapeutic antibody development. It also provides a functional framework for understanding how cells resist or succumb to complement attack, which is relevant to gene-edited cells and to cancer immunotherapy.
• CDC assays are standard in histocompatibility testing to detect donor-specific antibodies that can cause graft injury.
• Complement-fixing autoantibodies against myelin oligodendrocyte glycoprotein can mediate CDC and contribute to neurological autoimmunity.
• In immune thrombocytopenia, complement activation contributes to platelet destruction and is a target of emerging therapies.
• Therapeutic antibodies can be engineered to retain CDC activity while reducing unwanted toxicity.
• Tumor cells can acquire resistance to CDC by up-regulating CD59, a process linked to NANOG expression.
• Gene-edited pig cells are evaluated by CDC assays to predict human complement-mediated rejection in xenotransplantation.
• CDC is a functional endpoint that complements binding assays when characterizing antibody responses.
• Understanding CDC helps interpret complement inhibitor therapy and guide patient stratification.
What Happens During complement-dependent cytotoxicity?
Antibody binding and complement activation
In simple terms: An antibody sticks to the target cell and starts the complement chain reaction.
CDC begins when a target cell is recognized by antibodies that bind surface antigens. Bound antibodies, particularly IgM and certain IgG subclasses, provide a platform for complement activation through the classical pathway. This activation generates C3 convertase activity and deposits C3 fragments on the target membrane, marking the cell for further complement attack. The efficiency of this step depends on antibody density, antigen accessibility, and the complement-fixing capacity of the antibody.
Formation of the membrane attack complex
In simple terms: The complement proteins assemble into a pore that punches holes in the cell membrane.
Following complement activation, the terminal pathway components C5b, C6, C7, C8, and multiple C9 molecules assemble into the membrane attack complex (MAC) on the target cell membrane. The MAC is a pore-forming structure that inserts into the lipid bilayer and disrupts membrane integrity. This step is the defining event of GO:0097278, because the GO definition specifies that cell killing is caused by the MAC formed after complement activation. MAC assembly can be regulated by membrane-bound inhibitors, and the balance between activation and inhibition determines the extent of lysis.
Membrane damage and cell death
In simple terms: The pore lets ions and water rush in, and the cell bursts or dies.
Once the MAC is inserted, it creates channels that allow uncontrolled ion and water flux across the membrane, leading to osmotic swelling and loss of membrane integrity. The result is cell lysis or death, which can be measured by viability dyes, release of intracellular contents, or impedance-based assays. In some settings, sublytic MAC deposition can also trigger signaling responses, but the canonical outcome of CDC is target cell killing.
Quantification in the laboratory
In simple terms: Scientists mix cells with antibody and complement, then count how many cells die.
CDC is quantified by incubating target cells with a specific antibody and complement-active serum, followed by a readout of viability or lysis. Common formats include dye exclusion, chromium release, and flow cytometry-based viability staining. Controls typically include heat-inactivated serum to confirm complement dependence and antibody-free wells to assess background lysis. The assay is used clinically in crossmatch testing and experimentally to compare cell lines or gene-edited cells.
Key Genes Involved in GO:0097278 complement-dependent cytotoxicity
The following genes and proteins are central to complement-dependent cytotoxicity, either as complement cascade components, membrane regulators, or targets of CDC assays.
| Gene | Major Role | Research Relevance |
|---|---|---|
| C3 | Central complement component; deposition on target cells | Marker of complement activation in CDC assays |
| C5 | Cleaved to C5b, initiating MAC assembly | Target of complement inhibitors; key node in terminal pathway |
| C6 | MAC component; binds C5b | Defects cause complement deficiency; studied in CDC models |
| C7 | MAC component; inserts into membrane | Required for MAC pore formation |
| C8 | MAC component; recruits C9 | Essential for lytic pore assembly |
| C9 | Forms the MAC pore | Direct effector of membrane damage in CDC |
| CD59 | Membrane inhibitor of MAC | Up-regulated in CDC-resistant tumor cells |
| CD55 | Regulates C3 convertase | Modulates complement activation on cell surfaces |
| CD46 | Cofactor for factor I-mediated C3b cleavage | Controls complement amplification |
| NANOG | Transcription factor; up-regulates CD59 | Confers CDC resistance in immune-edited tumor cells |
| MOG | Autoantigen target in neurological autoimmunity | Autoantibodies against MOG mediate CDC |
| IgG1 | Antibody subclass that fixes complement | Engineered variants tested for CDC activity |
| IgM | Potent complement activator | Used in CDC assays and crossmatch testing |
| C1q | Initiates classical pathway | Binding to antibody-coated cells triggers CDC |
| Factor B | Alternative pathway component | Amplifies complement activation |
| Factor H | Regulates alternative pathway | Protects cells from complement attack |
| C4 | Classical pathway component | Supports C3 convertase formation |
How Is complement-dependent cytotoxicity Regulated?
CDC is regulated at multiple levels. Soluble and membrane-bound complement inhibitors, including CD55, CD46, and CD59, limit complement activation and MAC assembly on host cells. Antibody properties such as subclass, glycosylation, and Fc engineering influence complement fixation and the efficiency of CDC. In tumor cells, transcriptional programs driven by NANOG can increase CD59 expression and reduce CDC susceptibility. In transplantation, genetic modifications of donor cells can alter the expression of complement regulators and change CDC outcomes. These regulatory layers determine whether a given antibody-target pair results in efficient lysis or resistance.
complement-dependent cytotoxicity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CD59 | Tumor immune evasion from CDC | CD59 knockout or overexpression in tumor cell lines |
| NANOG | Regulation of CD59 and CDC resistance | NANOG knockout or inducible overexpression |
| MOG | Autoantibody-mediated neurological disease | MOG-expressing cells with patient-derived antibodies |
| C5 | Complement-mediated transplant injury | C5 knockout or inhibitor-treated cells in CDC assays |
| IgG1 | Therapeutic antibody CDC activity | Fc-engineered antibody variants in CDC assays |
Transplant rejection and crossmatch testing
Donor-specific antibodies that activate complement can cause CDC of graft endothelial cells, contributing to antibody-mediated rejection. CDC crossmatch assays are used to detect these antibodies before transplantation and to guide organ allocation. In xenotransplantation, CDC assays evaluate whether human complement lyses gene-edited pig cells, helping to predict rejection risk.
Autoimmune cytopenias and neurological autoimmunity
In immune thrombocytopenia, complement activation contributes to platelet destruction, and complement-fixing autoantibodies are a therapeutic target. Autoantibodies against myelin oligodendrocyte glycoprotein can mediate CDC in neurological autoimmune conditions, as shown by in vitro assays. These examples illustrate how CDC links autoantibody specificity to tissue damage.
Cancer immune evasion and therapy
Tumor cells can evade antibody-mediated CDC by up-regulating complement inhibitors such as CD59, a mechanism associated with NANOG expression in immune-edited tumor cells. Conversely, therapeutic antibodies can be designed to maximize CDC against tumor cells while minimizing toxicity. Understanding CDC resistance is therefore important for predicting responses to antibody-based cancer therapies.
From complement-dependent cytotoxicity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CD59 increase CDC sensitivity? | CD59 knockout cell line |
| Does NANOG drive CDC resistance? | NANOG knockout or overexpression |
| Can point mutations in complement components alter MAC assembly? | Point-mutation knock-in of C5, C6, C7, C8, or C9 |
| Does a specific antibody require complement for killing? | Target cells with heat-inactivated serum control |
| Can gene-edited pig cells resist human complement? | Knockout of complement regulators or knock-in of human inhibitors |
| Is a candidate gene causally involved in CDC? | CRISPR knockout followed by CDC assay |
How to Study the complement-dependent cytotoxicity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CDC assay with viability dye | Complement-dependent target cell lysis | Antibody characterization and crossmatch testing |
| Flow cytometry | Antibody binding and complement deposition | Detection of donor-specific antibodies |
| Chromium release assay | Membrane integrity and lysis | Classical CDC quantification |
| Heat-inactivated serum control | Complement dependence of killing | Confirming CDC specificity |
| CRISPR knockout | Loss-of-function effect on CDC | Testing candidate genes such as CD59 |
| Overexpression | Gain-of-function effect on CDC | Testing NANOG or complement inhibitors |
| Fc engineering | Antibody complement fixation | Optimizing therapeutic antibodies |
| Gene-edited pig cell CDC assay | Human complement-mediated lysis | Xenotransplantation evaluation |
CDC assay with viability readout
The core method is to incubate target cells with a specific antibody and complement-active serum, then measure viability or lysis. Readouts include dye exclusion, flow cytometry, and release assays. Heat-inactivated serum controls confirm that killing is complement-dependent.
Flow cytometry and crossmatch testing
Flow cytometry can quantify antibody binding and complement deposition on cells, and is used in crossmatch testing to detect donor-specific antibodies. This approach allows simultaneous assessment of multiple cell populations and is compatible with patient serum samples.
Gene editing and functional validation
CRISPR knockout or knock-in of complement regulators or effectors can be combined with CDC assays to test causality. For example, CD59 knockout increases CDC sensitivity, while NANOG manipulation alters CD59 levels and resistance. Gene-edited pig cells are evaluated by CDC assays to predict xenotransplantation compatibility.
Antibody engineering and complement profiling
Antibody variants can be tested for CDC activity to optimize Fc-mediated complement fixation while reducing toxicity. Complement deposition can be profiled by detecting C3 fragments or MAC components on target cells. These methods link antibody structure to functional CDC outcomes.
How CRISPR Can Be Used to Study GO:0097278 complement-dependent cytotoxicity
Knockout
CRISPR knockout of complement regulators such as CD59 or CD55 can increase CDC sensitivity and reveal their protective role. Knockout of complement effectors can reduce MAC formation and CDC. These models are validated by CDC assays with appropriate serum controls.
Point Mutation
Point mutations in complement components or antibody Fc regions can be introduced to test specific residues required for complement activation or MAC assembly. Such models help dissect structure-function relationships in CDC without deleting entire genes.
Knock-in
Knock-in of human complement regulators into donor cells can reduce CDC and is relevant to xenotransplantation. Tagged knock-in of complement proteins can facilitate tracking of MAC assembly and deposition.
Overexpression
Overexpression of NANOG or CD59 can confer CDC resistance and is used to model tumor immune evasion. Overexpression of complement inhibitors can protect cells from antibody-mediated lysis in transplantation settings.
How EDITGENE Supports complement-dependent cytotoxicity Research
Researchers studying complement-dependent cytotoxicity-related genes often need to determine whether a candidate gene is causally involved in CDC sensitivity or resistance. EDITGENE provides CRISPR-based cell model services that enable functional validation of complement regulators, effectors, and antibody targets in relevant cell backgrounds.
Contact EDITGENE today to design your custom CRISPR model for complement-dependent cytotoxicity research.
Frequently Asked Questions About complement-dependent cytotoxicity
What is complement-dependent cytotoxicity (GO:0097278)?
It is the cell killing caused by the membrane attack complex formed following complement activation.
What genes are involved in complement-dependent cytotoxicity?
Key genes include complement components C3, C5, C6, C7, C8, and C9, regulators CD46, CD55, and CD59, and modulators such as NANOG.
How is complement-dependent cytotoxicity measured?
By incubating target cells with antibody and complement-active serum, then measuring viability or lysis.
What is the membrane attack complex?
The MAC is a pore-forming assembly of C5b, C6, C7, C8, and C9 that inserts into target cell membranes and causes lysis.
Why is CDC important in transplantation?
Donor-specific antibodies that trigger CDC can cause graft injury, and CDC crossmatch assays help identify unacceptable mismatches.
Can tumors resist complement-dependent cytotoxicity?
Yes, tumor cells can up-regulate CD59, a process linked to NANOG, to evade CDC.
What is a CDC crossmatch?
It is a test that uses complement to detect antibodies in recipient serum that react with donor cells.
How do CRISPR models help study CDC?
Knockout, knock-in, point mutation, and overexpression models can test whether specific genes alter CDC sensitivity or resistance.
Is CDC relevant to autoimmune diseases?
Yes, complement-fixing autoantibodies can mediate CDC in conditions such as immune thrombocytopenia and MOG antibody-associated disease.
What controls CDC efficiency?
Antibody subclass, antigen density, complement regulator expression, and serum complement activity all influence CDC efficiency.
Conclusion
GO:0097278 complement-dependent cytotoxicity is a well-defined biological process in which the membrane attack complex kills antibody-coated target cells. Its measurement is straightforward in principle but requires careful controls to confirm complement dependence. The process is central to transplantation, autoimmunity, and cancer immunotherapy, and its regulation by complement inhibitors such as CD59 determines resistance or sensitivity. CRISPR-based cell models now allow precise dissection of the genes that control CDC, supporting both mechanistic research and translational applications.
References
- 1. Duensing TD et al.. 2018. Complement-Dependent Cytotoxicity Assay.. Cold Spring Harb Protoc 2018(2) PMID: 29438057
- 2. Peña JR et al.. 2013. Complement-dependent cytotoxicity crossmatch.. Methods Mol Biol 1034:257-83 PMID: 23775741
- 3. Kohyama K et al.. 2023. Complement-dependent cytotoxicity of human autoantibodies against myelin oligodendrocyte glycoprotein.. Front Neurosci 17:1014071 PMID: 36816137
- 4. Feng H et al.. 2025. Evaluation of Complement-Dependent Cytotoxicity Assays for Gene-Edited Pig-to-Human Xenotransplantation.. Xenotransplantation 32(1):e70021 PMID: 39960350
- 5. Feng H et al.. 2025. Evaluation of Complement-Dependent Cytotoxicity Assays for Gene-Edited Pig-to-Human Xenotransplantation.. Xenotransplantation 32(1):e70012 PMID: 39825616
- 6. Audia S et al.. 2021. Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments.. Hemasphere 5(6):e574 PMID: 34095758
- 7. Lo M et al.. 2017. Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice.. J Biol Chem 292(9):3900-3908 PMID: 28077575
- 8. Son SW et al.. 2022. NANOG confers resistance to complement-dependent cytotoxicity in immune-edited tumor cells through up-regulating CD59.. Sci Rep 12(1):8652 PMID: 35606403
